Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2017-01-19 Capital/Financing Update
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Karo Pharma offentliggör prospekt och ny finansiell information som återfinns i prospektet
Capital/Financing Update Classification · 95% confidence The document is a press release from Karo Pharma announcing that its prospectus for a rights issue has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). The text explicitly states that the prospectus contains new financial information, including capital structure and net debt as of October 31, 2016, and also mentions a proforma consolidated income statement and balance sheet included in the prospectus. Since the document itself is an announcement about the availability and content of a formal offering document (the prospectus), and it contains specific financial data highlights related to a financing/capital event (rights issue), it strongly aligns with the 'Capital/Financing Update' (CAP) category. While it mentions a prospectus, the primary focus is the announcement of the financing event and the key financial metrics released alongside it, rather than being the full offering document itself or a general regulatory filing (RNS). It is not an Earnings Release (ER) as it focuses on financing, not operational results.
2017-01-19 Swedish
Beslut vid Karo Pharmas extra bolagsstämma den 18 januari 2017
AGM Information Classification · 99% confidence The document is a press release dated January 18, 2017, detailing decisions made at an Extraordinary General Meeting (EGM) of Karo Pharma. The primary decision announced is the approval of a rights issue (nyemission) to raise approximately 374 MSEK. This action directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification for an announcement detailing a rights issue approved at a shareholder meeting.
2017-01-18 Swedish
Villkoren för Karo Pharmas fullt garanterade företrädesemission fastställda
Share Issue/Capital Change Classification · 98% confidence The document is a press release from Karo Pharma AB detailing the finalized terms of a rights issue ('företrädesemission'). It specifies the subscription price (20.50 SEK), the ratio (2:7), the expected capital raised (up to 374.3 MSEK), and includes a preliminary timeline for the process, including an upcoming Extraordinary General Meeting (EGM) to approve it. The key focus is on fundraising, capital structure changes, and the mechanics of issuing new shares via rights offerings. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions an upcoming EGM, the primary content is the financing terms, not the voting results (DVA) or the AGM presentation itself (AGM-R). It is not a full annual report (10-K) or an interim report (IR).
2017-01-16 Swedish
KALLELSE TILL EXTRA BOLAGSSTÄMMA I KARO PHARMA AKTIEBOLAG
AGM Information Classification · 95% confidence The document is titled "KALLELSE TILL EXTRA BOLAGSSTÄMMA I KARO PHARMA AKTIEBOLAG" which translates to "NOTICE TO AN EXTRAORDINARY GENERAL MEETING IN KARO PHARMA AB". It details the date, time, location, shareholder registration requirements, agenda items (including a proposal for a rights issue/företrädesemission), and where related documents can be found. This content directly corresponds to the purpose of a notice for a shareholder meeting, specifically an Extraordinary General Meeting (EGM). While the agenda includes a proposal for a capital change (rights issue), the primary function of the document is the meeting notice itself. The closest available category that covers general meeting information, especially when it involves voting or specific announcements related to the meeting structure, is AGM-R (AGM Information), although this is an EGM. Given the options, AGM-R is the most appropriate fit for a formal meeting notice, as there is no specific EGM code. It is not a DEF 14A (Remuneration), DVA (Voting Results), or CAP (Financing Update), as it is the *notice* calling the meeting to vote on the financing, not the financing announcement itself.
2016-12-15 Swedish
Karo Pharma köper läkemedelsbolaget BioPhausia (Nordic Brands)
Capital/Financing Update Classification · 98% confidence The document announces that Karo Pharma is acquiring BioPhausia for 908 MSEK, financed primarily through bank loans, with a planned rights issue (företrädesemission) in Q1 2017 to secure further financing. This clearly details a significant corporate financing and capital structure change related to an acquisition. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific financing event.
2016-11-01 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January to September 2016 for Karo Pharma. It contains comprehensive financial statements, including income statements, cash flow analysis, and management commentary on business performance, risks, and future outlook. It is not a mere announcement or certification, but the full interim financial report itself. 9M 2016
2016-10-27 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.